Brian Dowd
Private Equity Investor bei Connecticut Innovations, Inc.
Profil
Brian Dowd is currently the Director & Investments at Connecticut Innovations, Inc. Prior to this, he worked as the Director & Business Development at Pfizer Inc. and as the Associate Director at Myrexis, Inc. He also held positions as the Sr. Director, Business Devt & Portfolio Strategy at Biohaven Pharmaceuticals, Inc., Scientific Director at Simpson Healthcare Executives LLC, and VP Clinical and Scientific Affairs at Nuview Life Sciences, Inc. From 2017 to 2021, he was the VP Business Development and Operations at Kleo Pharmaceuticals, Inc. Dr. Dowd received his doctorate from Yale University in 2004 and his undergraduate degree from the University of Michigan in 1995.
Aktive Positionen von Brian Dowd
| Unternehmen | Position | Beginn |
|---|---|---|
Connecticut Innovations, Inc.
 Connecticut Innovations, Inc. Investment ManagersFinance Connecticut Innovations, Inc (CI) is venture capital firm founded in 1989. The firm is headquartered in Rocky Hill, Connecticut. | Private Equity Investor | 01.02.2023 |
Ehemalige bekannte Positionen von Brian Dowd
| Unternehmen | Position | Ende |
|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | 01.02.2023 |
Biohaven Pharmaceuticals, Inc.
 Biohaven Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Biohaven Pharmaceuticals, Inc. engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. The company in July 2013 and is headquartered in New Haven, CT. | Corporate Officer/Principal | 01.10.2022 |
Kleo Pharmaceuticals, Inc.
 Kleo Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Kleo Pharmaceuticals, Inc. is a biotechnology company, which engages in the development of biospecific compounds designed to emulate and enhance the activity of biologics. Its compounds are designed to direct the immune system to destroy cancerous or virally infected cells, and treatment of multiple myeloma and COVID-19. It offers Antibody Recruiting Molecules (ARMs),Synthetic Antibody Mimics (SyAMs), and Monoclonal Antibody Therapy Enhancers (MATEs) pipeline. The company was founded by David A. Spiegel and Roy Prieb in 2015 and is headquartered in New Haven, CT. | Corporate Officer/Principal | 01.01.2021 |
| Simpson Healthcare Executives LLC | Corporate Officer/Principal | 01.06.2015 |
Nuview Life Sciences, Inc.
 Nuview Life Sciences, Inc. Medical/Nursing ServicesHealth Services Nuview Life Sciences, Inc. is a clinical stage oncology company, which engages in the provision of precision cancer diagnostics and theranostics services. The company was founded by Paul J. Crowe in 2005 and is headquartered in Park City, UT. | Corporate Officer/Principal | 01.06.2014 |
Ausbildung von Brian Dowd
| Yale University | Doctorate Degree |
| University of Michigan | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| MYREXIS, INC. | Finance |
| Private Unternehmen | 5 |
|---|---|
Connecticut Innovations, Inc.
Connecticut Innovations, Inc. Investment ManagersFinance Connecticut Innovations, Inc (CI) is venture capital firm founded in 1989. The firm is headquartered in Rocky Hill, Connecticut. | Finance |
Nuview Life Sciences, Inc.
Nuview Life Sciences, Inc. Medical/Nursing ServicesHealth Services Nuview Life Sciences, Inc. is a clinical stage oncology company, which engages in the provision of precision cancer diagnostics and theranostics services. The company was founded by Paul J. Crowe in 2005 and is headquartered in Park City, UT. | Health Services |
Kleo Pharmaceuticals, Inc.
Kleo Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Kleo Pharmaceuticals, Inc. is a biotechnology company, which engages in the development of biospecific compounds designed to emulate and enhance the activity of biologics. Its compounds are designed to direct the immune system to destroy cancerous or virally infected cells, and treatment of multiple myeloma and COVID-19. It offers Antibody Recruiting Molecules (ARMs),Synthetic Antibody Mimics (SyAMs), and Monoclonal Antibody Therapy Enhancers (MATEs) pipeline. The company was founded by David A. Spiegel and Roy Prieb in 2015 and is headquartered in New Haven, CT. | Commercial Services |
Biohaven Pharmaceuticals, Inc.
Biohaven Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Biohaven Pharmaceuticals, Inc. engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. The company in July 2013 and is headquartered in New Haven, CT. | Commercial Services |
| Simpson Healthcare Executives LLC |
